Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Fenofibrate tablets, used for the treatment of high levels of cholesterol, in the American market. The drug has an estimated market size of $412 million for the 12 months ended March 2016, the company said, quoting US-based healthcare information provider IMS Health.